中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

64 records (took 0.034 seconds)

    Anticancer agent
    3.
    发明授权
    Anticancer agent 有权
    抗癌剂

    公开(公告)号：US08507443B2

    公开(公告)日：2013-08-13

    申请号：US11885080

    申请日：2005-08-19

    Applicant: Eisuke Mekada ,  Shingo Miyamoto

    Inventor： Eisuke Mekada ,  Shingo Miyamoto

    IPC: A61K38/16 ,  A61K31/337 ,  C07D471/22

    CPC classification number: A61K31/4745 ,  A61K31/337 ,  A61K38/164 ,  A61K45/06 ,  G08G1/015 ,  A61K2300/00

    Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.

    Abstract translation: 本发明是一种抗肿瘤剂，其特征在于包括紫杉醇和紫杉醇衍生物中的至少一种和作为白喉毒素突变体的蛋白质，具有抑制HB-EGF与EGFR之间的结合并且基本上不具有白喉毒性的蛋白质 毒素作为活性成分。

    Method for identifying attenuated chickenpox virus Oka strain or strain originating therein and acceptable as attenuated chickenpox vaccine virus
    4.
    发明授权
    Method for identifying attenuated chickenpox virus Oka strain or strain originating therein and acceptable as attenuated chickenpox vaccine virus 失效
    用于鉴定减毒水痘病毒Oka菌株或由其衍生的菌株的方法

    公开(公告)号：US6093535A

    公开(公告)日：2000-07-25

    申请号：US983045

    申请日：1998-01-15

    Applicant: Chisato Mori ,  Rie Takahara ,  Juichiro Osame ,  Yasuyuki Gomi ,  Isao Fuke

    Inventor： Chisato Mori ,  Rie Takahara ,  Juichiro Osame ,  Yasuyuki Gomi ,  Isao Fuke

    IPC: A61K39/00 ,  C07K14/04 ,  C12N15/38 ,  C12Q1/70 ,  C07H21/04 ,  C12N7/00 ,  C12P19/34

    CPC classification number: C07K14/005 ,  C12Q1/701 ,  A61K39/00 ,  C12N2710/16722

    Abstract: Disclosed is a method for exact identification of the attenuated varicella virus Oka strain or a strain derived therefrom capable of functioning as an attenuated varicella live vaccine virus, which comprises analyzing the difference in the genomic DNA and fragments thereof between the Oka strain and a sample varicella strain, and determining whether or not a sample strain satisfies all of the following eight characteristics: the sizes of the HpaI-K fragment and the EcoRI-P fragment; the size of R2-487 region of Gene14 and the analysis by PCR-SSCP; the sizes of the restriction fragments obtained by digesting the R2-1764 fragment with AccIII; the absence or presence of a PstI cleavage site; the homology of the amino acid sequences coded by R2-487 coding region; and the homology of the amino acid sequences coded by the coding region of VZV Gene14. The method of the present invention is extremely useful for the quality control and quality assurance of attenuated varicella live vaccines. Also disclosed are an isolated virus strain which is substantially the same virus strain as identified by the above method; an attenuated varicella virus live vaccine comprising the same virus strain as identified by the above method; an attenuated varicella virus Oka strain antigen; and a pair of primers which are advantageously, effectively usable in the above method.

    Abstract translation: PCT No.PCT / JP97 / 01646 Sec。 371日期1998年1月15日 102（e）日期1998年1月15日PCT提交1997年5月15日PCT公布。 公开号WO97 / 43420 PCT 日期1997年11月20日公开是一种精确鉴定减毒水痘病毒Oka菌株或由其衍生的能够作为减毒水痘活疫苗病毒的菌株的方法，其中包括分析Oka基因组DNA及其片段之间的差异 菌株和样本水痘菌株，并确定样品菌株是否满足以下八个特征：HpaI-K片段和EcoRI-P片段的大小; Gene14的R2-487区域的大小和通过PCR-SSCP的分析; 通过用AccIII消化R2-1764片段获得的限制性片段的大小; 不存在或存在PstI切割位点; 由R2-487编码区编码的氨基酸序列的同源性; 和由VZV Gene14的编码区编码的氨基酸序列的同源性。 本发明的方法对于减毒水痘活疫苗的质量控制和质量保证是非常有用的。 还公开了分离的病毒株，其通过上述方法鉴定为基本上相同的病毒株; 包含由上述方法鉴定的相同病毒株的减毒水痘病毒活疫苗; 减毒水痘病毒Oka株抗原; 以及有利地在上述方法中有效使用的一对引物。

    Stabilized live vaccine
    5.
    发明授权
    Stabilized live vaccine 失效
    稳定活疫苗

    公开(公告)号：US6039958A

    公开(公告)日：2000-03-21

    申请号：US179970

    申请日：1998-10-28

    Applicant: Kuniaki Koyama ,  Juichiro Osame

    Inventor： Kuniaki Koyama ,  Juichiro Osame

    IPC: A61K39/25 ,  A61K39/295 ,  A61P31/12 ,  A61P31/22 ,  A01N63/00 ,  A61K39/12

    CPC classification number: A61K39/25 ,  A61K39/0015 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/70 ,  C12N2710/16734

    Abstract: A stabilized live vaccine containing a varicella virus and a stabilizer, wherein the vaccine is substantially free of Ca.sup.2+ ions and Mg.sup.2+ ions is described. This stabilized live vaccine is excellent in storage stability and heat resistance. Also described is an improved stabilizer for a live varicella vaccine, comprising at least gelatin or hydrolyzed gelatin, each being substantially free of Ca.sup.2+ ions and Mg.sup.2+ ions. The stabilizer can advantageously be used to stabilize a live vaccine containing a varicella virus. The substantial freedom of Ca.sup.2+ ions and Mg.sup.2+ ions can be attained by masking Ca.sup.2+ ions and Mg.sup.2+ ions present in a live vaccine containing a varicella virus and a stabilizer, with a chelating reagent, or by using as a stabilizer gelatin and/or a gelatin derivative after being purified to remove Ca.sup.2+ ions and/or Mg.sup.2+ ions contained therein.

    Abstract translation: 含有水痘病毒和稳定剂的稳定的活疫苗，其中疫苗基本上不含Ca 2+离子，描述了Mg 2+离子。 这种稳定的活疫苗具有优异的储存稳定性和耐热性。 还描述了一种用于活水痘疫苗的改进的稳定剂，其包含至少明胶或水解明胶，其各自基本上不含Ca 2+离子和Mg 2+离子。 稳定剂可以有利地用于稳定含有水痘病毒的活疫苗。 通过用螯合剂掩蔽含有水痘病毒和稳定剂的活疫苗中的Ca 2+离子和Mg 2+离子，或通过使用明胶和/或明胶衍生物作为稳定剂，可以获得Ca 2+离子和Mg 2+离子的实质自由度 经纯化以除去其中所含的Ca 2+离子和/或Mg 2+离子。

    Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
    6.
    发明授权
    Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide 失效
    非A型，非乙型肝炎病毒基因组cDNA和抗原多肽

    公开(公告)号：US05998130A

    公开(公告)日：1999-12-07

    申请号：US904686

    申请日：1997-08-01

    Applicant: Hiroto Okayama ,  Isao Fuke ,  Chisato Mori ,  Akihisa Takamizawa ,  Iwao Yoshida

    Inventor： Hiroto Okayama ,  Isao Fuke ,  Chisato Mori ,  Akihisa Takamizawa ,  Iwao Yoshida

    IPC: A61K39/00 ,  C07K14/18 ,  C12N15/40 ,  C12Q1/70

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2770/24222 ,  Y10S930/223

    Abstract: Disclosed is an isolated non-A, non-B hepatitis virus genomic cDNA covering the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in FIG. 2(1) through FIG. 2(16) hereof, wherein the coding region is from the 333rd to 9362nd nucleotides, and the 5'- and 3'- noncoding sequences contain 332 nucleotides and 54 nucleotides, respectively. Part of the cDNA and an antigen polypeptide as an expression product thereof are useful as a diagnostic reagent for non-A, non-B hepatitis. The antigen polypeptide is also useful as an active ingredient for a non-A, non-B hepatitis virus vaccine.

    Abstract translation: 公开了一种分离的非A非乙型肝炎病毒基因组cDNA，其覆盖图1所示的第1至第9416位核苷酸的病毒基因核苷酸序列的整个区域。 图2（1）〜图 2（16），其中编码区是从333到9362个核苷酸，5'-和3'-非编码序列分别含有332个核苷酸和54个核苷酸。 作为其表达产物的cDNA和抗原多肽的一部分可用作非A非乙型肝炎的诊断试剂。 抗原多肽也可用作非A非乙型肝炎病毒疫苗的活性成分。

    Method for producing a Gag-Env fusion protein
    7.
    发明授权
    Method for producing a Gag-Env fusion protein 失效
    生产Gag-Env融合蛋白的方法

    公开(公告)号：US5834267A

    公开(公告)日：1998-11-10

    申请号：US487657

    申请日：1995-06-07

    Applicant: Atsushi Saito ,  Hideo Sinagawa ,  Atsuo Nakata

    Inventor： Atsushi Saito ,  Hideo Sinagawa ,  Atsuo Nakata

    IPC: A61K39/00 ,  C07K14/16 ,  C12N15/49 ,  C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/70

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322 ,  Y10S435/974

    Abstract: Disclosed is a substantially pure HIV antigen comprising a Gag-Env fusion otein consisting of a Gag peptide fused at its C-terminus to an Env peptide, wherein the Gag peptide comprises a contiguous sequence of at least ten amino acids of the amino acid sequence represented by Gag (308-437) and the Env peptide comprises a contiguous sequence of at least a part of the amino acid sequence represented by Env (512-699), the part containing at least one epitope which is reactive to an HIV antibody. The gag-env fusion DNA corresponding to the HIV antigen of the present invention allows the production of the desired high antigenicity HIV antigen in high yield. Therefore, the HIV antigen of the present invention can be advantageously used as an active component for a diagnostic reagent, a vaccine, an antibody preparation and a therapeutic reagent for AIDS. Also disclosed is a substantially pure HIV antigen comprising a Gag protein SEQ ID No.:1 coded for by the entire gag gene.

    Abstract translation: 公开了一种基本上纯的HIV抗原，其包含由其C-末端融合到Env肽的Gag肽组成的Gag-Env融合蛋白，其中Gag肽包含表示的氨基酸序列的至少十个氨基酸的连续序列 通过Gag（308-437），并且Env肽包含由Env（512-699）表示的至少一部分氨基酸序列的连续序列，该部分含有至少一个对HIV抗体具有反应性的表位。 对应于本发明的HIV抗原的gag-env融合DNA允许以高产率产生所需的高抗原性HIV抗原。 因此，本发明的HIV抗原可以有利地用作诊断试剂，疫苗，抗体制剂和用于AIDS的治疗试剂的活性成分。 还公开了包含由整个gag基因编码的Gag蛋白质SEQ ID No.1的基本上纯的HIV抗原。

    Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine
    8.
    发明授权
    Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine 失效
    培养百日咳博德特氏菌，百日咳类毒素和百日咳疫苗的方法

    公开(公告)号：US5139776A

    公开(公告)日：1992-08-18

    申请号：US305680

    申请日：1989-02-03

    Applicant: Masashi Chazono ,  Iwao Yoshida ,  Takeo Konobe ,  Juichiro Osame ,  Keisuke Takaku

    Inventor： Masashi Chazono ,  Iwao Yoshida ,  Takeo Konobe ,  Juichiro Osame ,  Keisuke Takaku

    IPC: A61K39/10 ,  C12N1/20

    CPC classification number: C12N1/20 ,  A61K39/099 ,  Y10S435/832

    Abstract: There is disclosed a method for culturing Bordetella pertussis in the presence of a cellulose and/or cellulose derivatives. The present method is useful for obtaining a mixed antigen comprising pertussis toxin and filamentous hemagglutinin in a large amount at low cost. From the antigen, there can be obtained a stable and effective pertussis toxoid to be used for a pertussis vaccine. There is also disclosed a vaccine comprising the pertussis toxoid as an active ingredient and a gelatin and/or gelatin derivatives as a stabilizing agent. The present vaccine is extremely stable and can be stored for a prolonged period of time.

    Abstract translation: 公开了一种在纤维素和/或纤维素衍生物存在下培养百日咳博德特氏菌的方法。 本方法以低成本大量获得包含百日咳毒素和丝状血凝素的混合抗原是有用的。 从抗原中可获得用于百日咳疫苗的稳定且有效的百日咳类毒素。 还公开了包含百日咳类毒素作为活性成分的疫苗和明胶和/或明胶衍生物作为稳定剂。 目前的疫苗非常稳定，可以长时间保存。

Patent Agency Ranking